Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Fengcai Zhu, Yu-Hua Li, Xu-Hua Guan, +18

The Lancet

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults

Nawal Al Kaabi, Yuntao Zhang, Shengli Xia, +38

JAMA

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial

Shipo Wu, Jianying Huang, Zhe Zhang, +16

The Lancet Infectious Diseases

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Scott A. Halperin, Lingyun Ye, Donna MacKinnon‐Cameron, +45

The Lancet

VaccinationVaccine SafetyVaccine DevelopmentVaccine TrialVirology +6

Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial

Fengcai Zhu, Alie Wurie, Lihua Hou, +17

The Lancet

VaccinationVaccine SafetyVaccine DevelopmentVaccine EfficacySierra Leone +4

Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial

Fengcai Zhu, Lihua Hou, Jingxin Li, +17

The Lancet

VaccinationVaccine SafetyVaccine DevelopmentPreliminary ReportImmunology +5

Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: a randomised, open-label, single-centre trial

Jingxin Li, Shipo Wu, Xiling Guo, +31

The Lancet Respiratory Medicine

VaccinationVaccine SafetyVaccine DevelopmentVaccine TargetImmunology +6

Seroepidemiological investigation of HAdV-4 infection among healthy adults in China and in Sierra Leone, West Africa

Busen Wang, Jianhua Li, Shipo Wu, +9

Emerging Microbes & Infections

VaccinationVirus EpidemiologyViral DiagnosticsMedicinePathogenesis +11

Safety and Immunogenicity of a Recombinant Adenovirus Type-5–Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial

Fengcai Zhu, Pengfei Jin, Tao Zhu, +12

Clinical Infectious Diseases

Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial

Jingxin Li, Lihua Hou, Fanyue Meng, +14

The Lancet Global Health